Education

Country of origin - Russia
Pharm-Group - X-ray contrast agents

Manufacturers - Tyumen Chemical and Pharmaceutical Plant (Russia)
International name - Sodium iopodate
Synonyms - Biloptin
Dosage forms - tablets 500 mg
Composition - Active substance: Sodium iopodate.
Indications for use: Cholecystography, cholangiography, diffuse thyrotoxic goiter.
Contraindications - Hypersensitivity (including to iodine-containing drugs), severe dysfunction of the liver and kidneys, severe cardiovascular diseases, hyperthyroidism, pregnancy, breastfeeding.
Side effects - Diarrhea, nausea, vomiting, heartburn, abdominal cramps, flatulence, dysuria, acute renal failure, dizziness, headache, thrombocytopenia, DIC syndrome, hypotension, bradycardia, acute coronary failure, cardiogenic shock, cardiac arrest (in patients with ischemic heart disease), thyrotoxic crisis (with hyperthyroidism), formation of uric acid stones (against the background of hyperuricemia), anaphylactoid reactions: itching, skin rash, urticaria, fever, arthralgia, shock.
Interaction - Cholestyramine reduces the quality of visualization of the gallbladder (impairs absorption).
Overdose - No information.
Special instructions - To reduce the risk of anaphylactoid reactions in patients with bronchial asthma and a history of allergic diseases, preliminary administration of corticosteroids and/or antihistamines is recommended. It is necessary to monitor kidney function before cholecystography, and in old age - thyroid function. It is not recommended to use meglumine iodipamide and urography products within 24 hours before or after iodipamide. Taking the drug affects the results of other diagnostic studies: it increases the delay of bromsulfophthalein when determining liver function (the test should be carried out no earlier than 2 days after cholecystography), reduces the uptake of radioactive iodine ions for 1 week to several months, lowers the level of total T3 and increases T4 and thyroid-stimulating hormone; increases rates of uric acid excretion in urine for several days; within 3 days, a general urinalysis may reveal pseudoalbuminuria.
Literature - Encyclopedia of Medicines, 2003.